Hemogenyx Pharmaceuticals PLC

Hemogenyx Pharmaceuticals Plc is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. Its lead product candidate is HG-CT-1 for relapsed or refractory acute myeloid leukemia. The company also develops a chimeric bait receptor for viral infections and certain cancer and neurological conditions, a CDX bi-specific antibody that eliminates hematopoietic stem cells and progenitors, and therapies to improve bone marrow and blood stem cell transplants. It also addresses solid and rare cancers and immune system and autoimmune diseases. Incorporated in 2013, it is headquartered in London, United Kingdom.